K Moser, M Soto, D Geba, P Allen, K Lindpaintner - britishjournalofcancerresearch.com
Abstract Background: Immune checkpoint inhibitors (ICIs) are a valuable treatment option for
patients with malignant tumors, but only selected patients respond to ICIs. Available …